VistaGen Therapeutics
VTGN
14 hedge funds and large institutions have $2.3M invested in VistaGen Therapeutics in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more funds holding
Funds holding: 12 → 14 (+2)
0.09% less ownership
Funds ownership: 0.53% → 0.44% (-0.09%)
14% less capital invested
Capital invested by funds: $2.68M → $2.3M (-$377K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$14.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.11K |
| 4 |
PCP
Proficio Capital Partners
Newton,
Massachusetts
|
+$176 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$289K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.16K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $1.02M | – | – | – |
|
2
Parallax Volatility Advisers
San Francisco,
California
| $516K | – | – | – |
|
|
NC
3
Nexthera Capital
New York
| $258K | – | – | – |
|
|
DADC
4
D.A. Davidson & Co
Great Falls,
Montana
| $184K | +$14.6K | +250 | +8% |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $84K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $69K | -$4.16K | -71 | -5% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $56K | – | – | – |
|
|
SM
8
Sabby Management
Miami Beach,
Florida
| $48K | -$289K | -4,932 | -85% |
|
9
HighTower Advisors
Chicago,
Illinois
| $38K | – | – | – |
|
10
Northern Trust
Chicago,
Illinois
| $20K | – | – | – |
|
|
11
UBS Group
Zurich,
Switzerland
| $11K | +$11.9K | +203 | New |
|
|
HFM
12
Hartford Financial Management
Hartford,
Connecticut
| $2K | – | – | – |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| $1K | +$1.11K | +19 | New |
|
|
PCP
14
Proficio Capital Partners
Newton,
Massachusetts
| – | +$176 | +3 | New |
|
VTGN Hedge Fund Activity: Q2 2017 in Review
14 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2017, worth a combined $2.3M — down 14% from $2.68M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VTGN positions and 1 closed out — a net gain of 2 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was D.A. Davidson & Co, adding an estimated $14.6K. The largest seller was Sabby Management, cutting an estimated $289K.
- 14 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2017, up from 12 in Q1 2017.
- Funds reported $2.3M of VistaGen Therapeutics stock for Q2 2017, down 14% quarter-over-quarter.
- 3 funds opened new VistaGen Therapeutics positions in Q2 2017 and 1 closed out, a net change of +2 holders.
- The largest VistaGen Therapeutics buyer in Q2 2017 was D.A. Davidson & Co, an estimated $14.6K added.
- The largest VistaGen Therapeutics seller in Q2 2017 was Sabby Management, an estimated $289K sold.
Based on aggregated 13F filings for Q2 2017.